Acceleron Pharma Inc (NASDAQ:XLRN) VP Adam M. Veness sold 824 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $45.20, for a total transaction of $37,244.80. Following the completion of the sale, the vice president now directly owns 16,124 shares of the company’s stock, valued at $728,804.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Acceleron Pharma stock opened at $46.20 on Friday. Acceleron Pharma Inc has a 52-week low of $37.01 and a 52-week high of $59.59. The company has a quick ratio of 17.11, a current ratio of 17.11 and a debt-to-equity ratio of 0.05. The company’s 50-day simple moving average is $44.35 and its 200-day simple moving average is $42.89. The firm has a market cap of $2.41 billion, a price-to-earnings ratio of -17.84 and a beta of 1.23.
Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). Acceleron Pharma had a negative return on equity of 29.51% and a negative net margin of 318.84%. The firm had revenue of $27.67 million for the quarter, compared to analyst estimates of $28.72 million. During the same quarter last year, the firm earned ($0.63) earnings per share. The company’s revenue was up 649.9% compared to the same quarter last year. Equities research analysts anticipate that Acceleron Pharma Inc will post -2.33 EPS for the current year.
A number of equities research analysts have recently commented on the stock. ValuEngine raised shares of Acceleron Pharma from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 8th. JPMorgan Chase & Co. reduced their target price on shares of Acceleron Pharma from $61.00 to $58.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Morgan Stanley set a $53.00 target price on shares of Acceleron Pharma and gave the company a “hold” rating in a report on Monday, July 15th. BidaskClub cut shares of Acceleron Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Finally, Goldman Sachs Group reaffirmed a “neutral” rating and issued a $54.00 target price on shares of Acceleron Pharma in a report on Wednesday, May 29th. Six investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $60.10.
Acceleron Pharma Company Profile
Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.
Further Reading: How analysts view the yield curve
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.